Da stoffet primært kan forventes at omsættes via peptidhydrolyse, antages nedsat lever funktion ikke at have nævneværdig indflydelse på farmakokinetikken.
As metabolism is expected to occur by peptide hydrolysis, an impaired liver function is not expected to affect the pharmacokinetics.